Our approach
Our experienced team apply a rigorous stock-driven investment approach. We have a particular focus on shifting company fundamentals that we believe are mis-priced by market consensus. The team works at the centre of the network of over 45 equity investment professionals, incorporates a non-binding assessment of environmental, social & governance (ESG) factors, and draws on the expertise of credit and macro investment teams across the firm. We do, however, also offer a sustainable investment solution where portfolio decisions are dictated by certain sustainability criteria which is classified as Article 8 under the European SFDR regulations. Our portfolios are driven by the teams’ highest conviction stock ideas supported by high levels of corporate engagement and rigorous risk oversight.
Potential benefits
Our range of global equity strategies aims to deliver capital growth and income outcomes for our clients.
Key risks
For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.
The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency and exchange rates. Investors may not get back the original amount invested.
The funds invest in emerging markets; these markets may be volatile and carry higher risk than developed markets.
Strategies in focus
Climate Transition Equities
A range of strategies investing in companies that can play a major role in the transition to a low-carbon world.

Need more information?
For further information, please contact our investment sales team.
Explore our equities range
Equities views

Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
Read more

UK Equities: Five questions with Charlotte Meyrick and Trevor Green
14 Jun 2022
Charlotte Meyrick and Trevor Green explain why 2022 has all been about getting your sector calls right in UK equities.
Read more

What does the data say? Where have the safe havens gone?
27 May 2022
In this month’s instalment of our visual series on topical themes, we look at how various asset classes are holding up in a turbulent year for financial markets.
Read more

The outlook for UK equities
21 Apr 2022
The UK equity market has been unloved by investors for much of the past decade. However, several positive factors suggest UK equities could return to favour.
Read more

Back to nature: Why we must act now on the biodiversity crisis
31 Mar 2022
In an age of mass extinctions, policymakers, businesses and financial institutions are beginning to acknowledge the risks associated with biodiversity loss, along with the opportunities that arise from nature-positive solutions.
Read more

Now for the hard part…..The challenge of delivering net zero
29 Mar 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
Read more

Ukraine-Russia crisis: The implications for global equities
29 Mar 2022
Our global equities team discuss the main direct and indirect consequences of the Ukraine-Russia crisis for stocks.
Read more

Politics, activists and ESG: The outlook for UK equities
10 Mar 2022
We bring together members of our UK equities team to discuss the key opportunities and risks in the market.
Read more

China, inflation and politics: Three reasons for EM turbulence
24 Feb 2022
Emerging market assets have underperformed developed market peers over the past decade. While this has led to valuation gaps, selectivity will be critical, argues David Nowakowski.
Read more

Where the wild things are: Why investors should care about natural capital
14 Dec 2021
Finance must wake up to the risks associated with biodiversity loss and the opportunities that arise from nature-friendly solutions, argue Eugenie Mathieu, Julie Zhuang and Jonathan Toub.
Read more

The future of pharma: Increased returns or the age of biotech?
8 Dec 2021
After decades of low returns on research and development (R&D), the healthcare sector is producing a slew of innovations, from drugs to diagnostics. But with many coming from new entrants, will big pharmaceutical companies manage to keep up with the times?
Read more

The long decline: Why trend economic growth is set to go on falling
12 Nov 2021
Trend rates of economic growth, which have been on the decline for decades in the world’s leading economies, look set to fall further. That will have big implications for governments, companies, households and investors, argues Stewart Robertson.
Read more

Regulatory shifts in China: A new fork in the road?
12 Oct 2021
Investors in China should view recent interventions by the government in the context of its history and longer-term strategic ambitions, argues Amy Kam.
Read more

The AIQ Podcast: China's tech crackdown
21 Sep 2021
China’s regulators are taking swift, radical action against tech companies they consider to be too big and powerful. How should foreign investors respond?
Read more

The taming of the few
27 Aug 2021
Despite accusations Big Tech companies are too powerful, their stranglehold across sectors will be hard to loosen. However, while investors need to keep a watchful eye on developments, Big Tech’s stranglehold on numerous economic sectors will be hard to loosen.
Read more

Are bond investors too complacent about inflation?
11 Aug 2021
US Treasury yields have fallen appreciably in recent weeks, seemingly dismissing the threat of rising consumer prices. Some investors could be in for a nasty surprise if inflation proves more intransigent than anticipated, argue Michael Grady and Katarina Cohrs.
Read more